{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:57:26Z","timestamp":1793116646056,"version":"4.5.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T00:00:00Z","timestamp":1747612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI radiopharm. chem."],"DOI":"10.1186\/s41181-025-00349-4","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T22:20:42Z","timestamp":1747693242000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Preparation and preclinical evaluation of 18F-labeled folate-RGD peptide conjugate for PET imaging of triple-negative breast carcinoma"],"prefix":"10.1186","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7980-5917","authenticated-orcid":false,"given":"Subhani M.","family":"Okarvi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousef","family":"Maliki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,19]]},"reference":[{"key":"349_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s41181-021-00127-y","volume":"6","author":"I AlJammaz","year":"2021","unstructured":"AlJammaz I, Al-Otaibi B, Al-Malki Y, Abousekhrah A, Okarvi SM. Fast fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its folate hybrid peptide conjugate for targeting breast carcinoma. EJNMMI Radiopharmacy Chem. 2021;6:12.","journal-title":"EJNMMI Radiopharmacy Chem"},{"key":"349_CR2","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.107.045526","volume":"49","author":"AJ Beer","year":"2008","unstructured":"Beer AJ, Niemeyer M, Carlsen J, Sarbia M, Nahrig J, Watzlowik P, Wester HJ, Harbeck N, Schwaiger M. Patterns of \u0391v\u03b23 expression in primary and metastatic human breast cancer as shown by 18F-Galacto-RGD PET. J Nucl Med. 2008;49:255\u20139.","journal-title":"J Nucl Med"},{"key":"349_CR3","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.3390\/cancers12061508","volume":"12","author":"SD Boss","year":"2020","unstructured":"Boss SD, Ametamey SM. Development of folate receptor\u2013\u2009targeted PET radiopharmaceuticals for tumor imaging \u2013 A bench-to-bedside journey. Cancers. 2020;12:1508.","journal-title":"Cancers"},{"key":"349_CR4","doi-asserted-by":"crossref","unstructured":"Chan W, White P. Fmoc solid phase peptide synthesis: A practical approach. Oxford Academic; 1999.","DOI":"10.1093\/oso\/9780199637256.001.0001"},{"key":"349_CR6","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.nucmedbio.2003.07.003","volume":"31","author":"X Chen","year":"2004","unstructured":"Chen X, Park R, Shahinian AH, Bading JR, Conti PS. Pharmacokinetics and tumor retention of 125I-labeled RGD peptides are improved by pegylation. Nucl Med Biol. 2004;31:11\u20139.","journal-title":"Nucl Med Biol"},{"key":"349_CR5","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.13242","volume":"6","author":"H Chen","year":"2016","unstructured":"Chen H, Niu G, Wu H, Chen X. Clinical application of radiolabeled RGD peptides for PET imaging of integrin \u03b1v\u03b23. Theranostics. 2016;6:78\u201392.","journal-title":"Theranostics"},{"key":"349_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.7150\/thno.4024","volume":"2","author":"M Fani","year":"2012","unstructured":"Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics. 2012;2:481\u2013501.","journal-title":"Theranostics"},{"key":"349_CR8","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.clbc.2017.03.007","volume":"17","author":"PS Ginter","year":"2017","unstructured":"Ginter PS, McIntire PJ, Cui X, Irshaid L, Liu Y, Chen Z, Shin SJ. Folate receptor alpha expression is associated with increased risk of recurrence in triple-negative breast cancer. Clin Breast Cancer. 2017;17:544\u20139.","journal-title":"Clin Breast Cancer"},{"key":"349_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13550-020-00624-2","volume":"10","author":"S Gnesin","year":"2020","unstructured":"Gnesin S, M\u00fcller J, Burger IA, et al. Radiation dosimetry of 18F-AzaFol: A first-in-human use of a folate receptor PET tracer. EJNMMI Res. 2020;10:32.","journal-title":"EJNMMI Res"},{"key":"349_CR9","unstructured":"Institute for Laboratory Animal Research. Guide for the care and use of laboratory animals. 8th ed. Washington (DC): National Academies Press; 2011."},{"key":"349_CR10","doi-asserted-by":"publisher","first-page":"872","DOI":"10.2741\/3283","volume":"14","author":"R Haubner","year":"2009","unstructured":"Haubner R, Decristoforo C. Radiolabelled RGD peptides and peptidomimetics for tumour targeting. Front Biosci. 2009;14:872\u201386.","journal-title":"Front Biosci"},{"key":"349_CR12","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1021\/bc034170n","volume":"15","author":"R Haubner","year":"2004","unstructured":"Haubner R, Kuhnast B, Mang C, Weber WA, Kessler H, Wester HJ, Schwaiger M. [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates. Bioconjug Chem. 2004;15:61\u20139.","journal-title":"Bioconjug Chem"},{"key":"349_CR11","doi-asserted-by":"crossref","unstructured":"Haubner R, Weber WA, Beer AJ, Vabuliene E, Reim D, Sarbia M, Becker KF, Goebel M, Hein R, Wester HJ, Kessler H, Schwaiger M. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med. 2005;2:e70.","DOI":"10.1371\/journal.pmed.0020070"},{"key":"349_CR13","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1021\/acs.molpharmaceut.9b00653","volume":"16","author":"GS Heo","year":"2019","unstructured":"Heo GS, Detering L, Luehmann HP, Primeau T, et al. Folate receptor \u03b1-Targeted 89Zr-M9346A Immuno-PET for Image-Guided intervention with Mirvetuximab Soravtansine in Triple-Negative breast Cancer. Mol Pharm. 2019;16:3996\u20134006.","journal-title":"Mol Pharm"},{"key":"349_CR15","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00259-009-1122-0","volume":"36","author":"C Hultsch","year":"2009","unstructured":"Hultsch C, Schottelius M, Auernheimer J, Alke A, Wester H-J. 18F-Fluoroglucosylation of peptides, exemplified on cyclo(RGDfK). Eur J Nucl Med Mol Imaging. 2009;36:1469\u201374.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"349_CR16","doi-asserted-by":"crossref","unstructured":"Josefsson A, Cortez AG, Yu J, Majumdar S, Bhise A, Hobbs RF, Nedrow JR. Evaluation of targeting \u03b1V\u03b23 in breast cancers using RGD peptide-based agents. Nucl Med Biol. 2024;128\u2013129:108880.","DOI":"10.1016\/j.nucmedbio.2024.108880"},{"key":"349_CR17","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2967\/jnumed.107.049452","volume":"49","author":"LM Kenny","year":"2008","unstructured":"Kenny LM, Coombes RC, Oulie I, Contractor KB, Miller M, Spinks TJ, McParland B, Cohen PS, Hui AM, Palmieri C, Osman S, Glaser M, Turton D, Al-Nahhas A, Aboagye EO. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J Nucl Med. 2008;49:879\u201386.","journal-title":"J Nucl Med"},{"key":"349_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.molonc.2012.02.005","volume":"6","author":"MF Kircher","year":"2012","unstructured":"Kircher MF, Hricak H, Larson SM. Molecular imaging for personalized cancer care. Mol Oncol. 2012;6:182\u201395.","journal-title":"Mol Oncol"},{"key":"349_CR19","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","volume":"26","author":"JA Ledermann","year":"2015","unstructured":"Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol. 2015;26:2034\u201343.","journal-title":"Ann Oncol"},{"key":"349_CR21","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2967\/jnumed.107.048009","volume":"49","author":"Z-B Li","year":"2008","unstructured":"Li Z-B, Wu Z, Chen K, Ryu EK, Chen X. 18F-labeled BBN-RGD heterodimer for prostate cancer imaging. J Nucl Med. 2008;49:453\u201361.","journal-title":"J Nucl Med"},{"key":"349_CR20","doi-asserted-by":"publisher","first-page":"837952","DOI":"10.3389\/fonc.2022.837952","volume":"12","author":"L Li","year":"2022","unstructured":"Li L, Chen X, Yu J, Yuan S. Preliminary clinical application of RGD-Containing peptides as PET radiotracers for imaging tumors. Front Oncol. 2022;12:837952.","journal-title":"Front Oncol"},{"key":"349_CR22","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1021\/acs.bioconjchem.5b00327","volume":"26","author":"S Liu","year":"2015","unstructured":"Liu S. Radiolabeled Cyclic RGD peptide bioconjugates as radiotracers targeting multiple integrins. Bioconjug Chem. 2015;26:1413\u201338.","journal-title":"Bioconjug Chem"},{"key":"349_CR23","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1021\/bc9000245","volume":"20","author":"Z Liu","year":"2009","unstructured":"Liu Z, Yan Y, Liu S, Wang F, Chen X. 18F, 64Cu, and 68Ga labeled RGD-bombesin heterodimeric peptides for PET imaging of breast cancer. Bioconjug Chem. 2009;20:1016\u201325.","journal-title":"Bioconjug Chem"},{"key":"349_CR24","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.7150\/thno.18401","volume":"7","author":"Y Ma","year":"2017","unstructured":"Ma Y, Ai G, Zhang C, Zhao M, Dong X, Han Z, Wang Z, Zhang M, Liu Y, Gao W, Li S, Gu Y. Novel linear peptides with high affinity to \u03b1v\u03b23 integrin for precise tumor identification. Theranostics. 2017;7:1511\u201323.","journal-title":"Theranostics"},{"key":"349_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1148\/radiol.10090050","volume":"255","author":"R Meier","year":"2010","unstructured":"Meier R, Henning TD, Boddington S, Tavri S, Arora S, Piontek G, Rudelius M, Corot C, Daldrup-Link HE. Breast cancers: MR imaging of folate-receptor expression with the folate-specific nanoparticle P1133. Radiology. 2010;255:527\u201335.","journal-title":"Radiology"},{"key":"349_CR26","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s13139-019-00614-w","volume":"53","author":"D Miladinova","year":"2019","unstructured":"Miladinova D. Molecular imaging in breast Cancer. Nucl Med Mol Imaging. 2019;53:313\u20139.","journal-title":"Nucl Med Mol Imaging"},{"key":"349_CR27","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1039\/C5SC04392A","volume":"7","author":"SV Moradi","year":"2016","unstructured":"Moradi SV, Hussein WM, Varamini P, Simerska P, Toth I. Glycosylation, an effective synthetic strategy to improve the bioavailability of therapeutic peptides. Chem Sci. 2016;7:2492\u2013500.","journal-title":"Chem Sci"},{"key":"349_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.2967\/jnumed.108.056077","volume":"50","author":"MS Morrison","year":"2009","unstructured":"Morrison MS, Ricketts SA, Barnett J, Cuthbertson A, Tessier J, Wedge SR. Use of a novel Arg-Gly-Asp Radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy. J Nucl Med. 2009;50:116\u201322.","journal-title":"J Nucl Med"},{"key":"349_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2967\/jnumed.110.076018","volume":"52","author":"C Muller","year":"2011","unstructured":"Muller C, Schibli R. Folic acid conjugates for nuclear imaging of folate receptor-positive cancer. J Nucl Med. 2011;52:1\u20134.","journal-title":"J Nucl Med"},{"key":"349_CR30","doi-asserted-by":"publisher","first-page":"e0122209","DOI":"10.1371\/journal.pone.0122209","volume":"10","author":"BM Necela","year":"2015","unstructured":"Necela BM, Crozier JA, Andorfer CA, et al. Folate receptor-\ud6fc (FOLR1) expression and function in triple-negative tumors. PLoS ONE. 2015;10:e0122209.","journal-title":"PLoS ONE"},{"key":"349_CR31","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41523-020-0147-1","volume":"6","author":"N Norton","year":"2020","unstructured":"Norton N, Youssef B, Hillman DW, Nassar A, Geiger XJ, Necela BM, Liu H, Ruddy KJ, Polley MC, Ingle JN, Couch FJ, Perez EA, Liu MC, Carter JM, Leon-Ferre RA, Boughey JC, Somers EB, Kalari KR, Visscher DW, Goetz MP, Knutson KL. Folate receptor alpha expression associates with improved disease-free survival in triple-negative breast cancer patients. NPJ Breast Cancer. 2020;6:4.","journal-title":"NPJ Breast Cancer"},{"key":"349_CR32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/ph16010056","volume":"16","author":"J Notni","year":"2022","unstructured":"Notni J. RGD forever! -Past, present, and future of a 3-Letter-Code in radiopharmacy and life sciences. Pharmaceuticals (Basel). 2022;16:56.","journal-title":"Pharmaceuticals (Basel)"},{"key":"349_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2193-1801-1-22","volume":"1","author":"DJ O\u2019Shannessy","year":"2012","unstructured":"O\u2019Shannessy DJ, Somers EB, Maltzman J, Smale R, Fu Y-S. Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple-negative disease. SpringerPlus. 2012;1:1\u20139.","journal-title":"SpringerPlus"},{"key":"349_CR37","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1007\/s002590100508","volume":"28","author":"SM Okarvi","year":"2001","unstructured":"Okarvi SM. Recent progress in fluorine-18 labelled peptide radiopharmaceuticals. Eur J Nucl Med. 2001;28:929\u201338.","journal-title":"Eur J Nucl Med"},{"key":"349_CR34","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.nucmedbio.2009.12.006","volume":"37","author":"SM Okarvi","year":"2010","unstructured":"Okarvi SM, AlJammaz I. Synthesis and evaluation of a technetium-99m labeled cytotoxic Bombesin peptide conjugate for targeting Bombesin receptor-expressing tumors. Nucl Med Biol. 2010;37:277\u201388.","journal-title":"Nucl Med Biol"},{"key":"349_CR35","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13550-019-0539-0","volume":"9","author":"SM Okarvi","year":"2019","unstructured":"Okarvi SM, AlJammaz IA. Convenient and efficient total solid-phase synthesis of DOTA-functionalized tumor-targeting peptides for PET imaging of cancer. EJNMMI Res. 2019;9:88.","journal-title":"EJNMMI Res"},{"key":"349_CR36","first-page":"49","volume":"21","author":"SM Okarvi","year":"2006","unstructured":"Okarvi SM, Jammaz IA. Preparation and in vitro and in vivo evaluation of technetium-99m-labeled folate and methotrexate conjugates as tumor imaging agents. Cancer Biother Radiopharm. 2006;21:49\u201360.","journal-title":"Cancer Biother Radiopharm"},{"key":"349_CR39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3390\/jpm13020369","volume":"13","author":"S Salih","year":"2023","unstructured":"Salih S, Elliyanti A, Alkatheeri A, AlYafei F, Almarri B, Khan H. The role of molecular imaging in personalized medicine. J Pers Med. 2023;13:369.","journal-title":"J Pers Med"},{"key":"349_CR40","doi-asserted-by":"crossref","unstructured":"Sorolla A, Wanga E, Clemons TD, Evans CW, et al. Triple-hit therapeutic approach for triple-negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine: Nanotechnology, Biology and Medicine. 2019;20:102003.","DOI":"10.1016\/j.nano.2019.04.006"},{"key":"349_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/1471-2407-11-293","volume":"11","author":"A Taherian","year":"2011","unstructured":"Taherian A, Li X, Liu Y, Haas TA. Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer. 2011;11:293.","journal-title":"BMC Cancer"},{"key":"349_CR42","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1021\/bc400380f","volume":"25","author":"M Wendeler","year":"2014","unstructured":"Wendeler M, Grinberg L, Wang X, Dawson PE, Baca M. Enhanced catalysis of oxime-based bioconjugations by substituted anilines. Bioconjug Chem. 2014;25:93\u2013101.","journal-title":"Bioconjug Chem"},{"key":"349_CR43","doi-asserted-by":"crossref","unstructured":"Wu P-H, Onodera Y, Ichikawa Y, Rankin EB, Giaccia AJ, Watanabe Y et al. Targeting integrins with RGD-conjugated gold nanoparticles in radiotherapy decreases the invasive activity of breast cancer cells. Int J Nanomed 2017:1250:69\u20135085.","DOI":"10.2147\/IJN.S137833"},{"key":"349_CR44","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1016\/j.bmcl.2009.07.108","volume":"19","author":"F Wuest","year":"2009","unstructured":"Wuest F, Hultsch C, Berndt M, Bergmann R. Direct labelling of peptides with 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG). Bioorg Med Chem Lett. 2009;19:5426\u20138.","journal-title":"Bioorg Med Chem Lett"},{"key":"349_CR45","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3389\/fphar.2020.00898","volume":"11","author":"H Yan","year":"2020","unstructured":"Yan H, You Y, Li X, Liu L, Guo Fen, Zhang Q, Liu D, Tong Y, Ding S, Wang J. Preparation of RGD peptide\/folate acid Double-Targeted mesoporous silica nanoparticles and its application in human breast Cancer MCF-7 cells. Front Pharmacol. 2020;11:898.","journal-title":"Front Pharmacol"},{"key":"349_CR46","doi-asserted-by":"publisher","first-page":"890","DOI":"10.5858\/arpa.2013-0309-OA","volume":"138","author":"Z Zhang","year":"2014","unstructured":"Zhang Z, Wang J, Tacha DE, et al. Folate receptor \ud6fc associated with triple-negative breast cancer and poor prognosis. Arch Pathol Lab Med. 2014;138:890\u20135.","journal-title":"Arch Pathol Lab Med"},{"key":"349_CR47","first-page":"5139","volume":"62","author":"S Zitzmann","year":"2002","unstructured":"Zitzmann S, Ehemann V, Schwab M. Arginine-glycine-aspartic acid (RGD)-peptide binds to both tumor and tumor-endothelial cells in vivo. Cancer Res. 2002;62:5139\u201343.","journal-title":"Cancer Res"}],"container-title":["EJNMMI Radiopharmacy and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41181-025-00349-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41181-025-00349-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T11:03:37Z","timestamp":1747739017000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejnmmipharmchem.springeropen.com\/articles\/10.1186\/s41181-025-00349-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["349"],"URL":"https:\/\/doi.org\/10.1186\/s41181-025-00349-4","relation":{},"ISSN":["2365-421X"],"issn-type":[{"value":"2365-421X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,19]]},"assertion":[{"value":"16 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All applicable institutional and international guidelines for the use and care of animals were applied. This research work was approved by the KFSH&RC Basic Research and, Animal Care and Use Committee (ACUC). RAC Approval No. 2200049.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"25"}}